

# Sebastian M Jud

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6651521/publications.pdf>

Version: 2024-02-01

66  
papers

2,796  
citations

257450

24  
h-index

175258

52  
g-index

67  
all docs

67  
docs citations

67  
times ranked

4981  
citing authors

#	ARTICLE	IF	CITATIONS
1	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. <i>Journal of the National Cancer Institute</i> , 2011, 103, 250-263.	6.3	596
2	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	21.4	374
3	Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection. <i>PLoS ONE</i> , 2012, 7, e29770.	2.5	219
4	The Contributions of Breast Density and Common Genetic Variation to Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	174
5	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 3289-3303.	2.9	152
6	Common Breast Cancer Susceptibility Variants in <i>LSP1</i> and <i>RAD51L1</i> Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1156-1166.	2.5	101
7	Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. <i>Breast</i> , 2009, 18, 135-141.	2.2	76
8	Characterizing mammographic images by using generic texture features. <i>Breast Cancer Research</i> , 2012, 14, R59.	5.0	65
9	BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 85-94.	2.5	56
10	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. <i>Cancer Research</i> , 2015, 75, 2457-2467.	0.9	55
11	Mammographic density as a risk factor for breast cancer in a German case-control study. <i>European Journal of Cancer Prevention</i> , 2011, 20, 1-8.	1.3	53
12	Breast Volumetry Using a Three-Dimensional Surface Assessment Technique. <i>Aesthetic Plastic Surgery</i> , 2011, 35, 847-855.	0.9	50
13	Association of mammographic density with hormone receptors in invasive breast cancers: Results from a case-only study. <i>International Journal of Cancer</i> , 2012, 131, 2643-2649.	5.1	44
14	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. <i>PLoS Genetics</i> , 2014, 10, e1004285.	3.5	39
15	Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 481-492.	1.8	38
16	Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 885-892.	2.5	36
17	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 617-625.	2.5	35
18	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. <i>Breast Care</i> , 2018, 13, 8-14.	1.4	32

#	ARTICLE	IF	CITATIONS
19	The Hohl instrument for optimizing total laparoscopic hysterectomy: results of more than 500 procedures in a university training center. <i>Archives of Gynecology and Obstetrics</i> , 2012, 285, 123-127.	1.7	31
20	Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 204.	2.6	30
21	Polymorphism in <i>HTR3D</i> shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. <i>Pharmacogenomics</i> , 2010, 11, 943-950.	1.3	29
22	Hormone replacement therapy and prognosis in ovarian cancer patients. <i>European Journal of Cancer Prevention</i> , 2013, 22, 52-58.	1.3	28
23	The PI3K Pathway: Background and Treatment Approaches. <i>Breast Care</i> , 2016, 11, 398-404.	1.4	28
24	Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 101-110.	2.5	26
25	Pain perception and detailed visual pain mapping in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 105-110.	2.5	24
26	Gynecologic oncologists' attitudes and practices relating to integrative medicine: results of a nationwide AGO survey. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 295-301.	1.7	24
27	Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 899-908.	2.5	23
28	Assessment of mammographic density before and after first full-term pregnancy. <i>European Journal of Cancer Prevention</i> , 2010, 19, 405-412.	1.3	21
29	FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. <i>BMC Cancer</i> , 2014, 14, 66.	2.6	19
30	Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases. <i>BMC Cancer</i> , 2015, 15, 587.	2.6	19
31	Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography. <i>International Journal of Cancer</i> , 2016, 139, 1967-1974.	5.1	19
32	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 453-461.	2.5	15
33	HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment. <i>Scientific Reports</i> , 2020, 10, 15750.	3.3	15
34	Relevance of Health Economics in Breast Cancer Treatment - the View of Certified Breast Centres and Their Patients. <i>Breast Care</i> , 2013, 8, 15-21.	1.4	14
35	Low-dose methotrexate treatment in ectopic pregnancy: a retrospective analysis of 164 ectopic pregnancies treated between 2000 and 2008. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 329-335.	1.7	14
36	Association of molecular subtypes with breast cancer risk factors. <i>European Journal of Cancer Prevention</i> , 2015, 24, 484-490.	1.3	14

#	ARTICLE	IF	CITATIONS
37	Inhibition of hyperalgesia by conditioning electrical stimulation in a human pain model. <i>Pain</i> , 2011, 152, 1298-1303.	4.2	13
38	Correlation of mammographic density and serum calcium levels in patients with primary breast cancer. <i>Cancer Medicine</i> , 2017, 6, 1473-1481.	2.8	13
39	Macromastia: an economic burden? A disease cost analysis based on real-world data in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 521-531.	1.7	13
40	Mammographic density and prognosis in primary breast cancer patients. <i>Breast</i> , 2021, 59, 51-57.	2.2	13
41	Assessment of breast volume changes during human pregnancy using a three-dimensional surface assessment technique in the prospective CGATE study. <i>European Journal of Cancer Prevention</i> , 2014, 23, 151-157.	1.3	12
42	Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 701-708.	2.5	12
43	Financing of certified centers: a willingness-to-pay analysis. <i>Archives of Gynecology and Obstetrics</i> , 2013, 287, 495-509.	1.7	11
44	Comprehensive visualization of paresthesia in breast cancer survivors. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 135-141.	1.7	11
45	Initial clinical results with a fusion prototype for mammography and three-dimensional ultrasound with a standard mammography system and a standard ultrasound probe. <i>Acta Radiologica</i> , 2018, 59, 1406-1413.	1.1	10
46	Factors influencing breast changes after pregnancy. <i>European Journal of Cancer Prevention</i> , 2013, 22, 259-261.	1.3	9
47	A Standard Mammography Unit " Standard 3D Ultrasound Probe Fusion Prototype: First Results. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 679-685.	1.8	9
48	Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095793.	3.2	9
49	Correlates of mammographic density in B-mode ultrasound and real time elastography. <i>European Journal of Cancer Prevention</i> , 2012, 21, 343-349.	1.3	8
50	Breast MRI texture analysis for prediction of BRCA-associated genetic risk. <i>BMC Medical Imaging</i> , 2020, 20, 86.	2.7	8
51	Logbooks alone are not enough: initial experience with implementing a logbook for medical students in a clinical internship in gynecology and obstetrics. <i>European Journal of Medical Research</i> , 2020, 25, 15.	2.2	8
52	Introducing multiple-choice questions to promote learning for medical students: effect on exam performance in obstetrics and gynecology. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 1401-1406.	1.7	7
53	Visual pain mapping in endometriosis. <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 687-693.	1.7	6
54	Using automated texture features to determine the probability for masking of a tumor on mammography, but not ultrasound. <i>European Journal of Medical Research</i> , 2017, 22, 30.	2.2	6

#	ARTICLE	IF	CITATIONS
55	Analysis of motives and patient satisfaction in oncological second opinions provided by a certified university breast and gynecological cancer center. Archives of Gynecology and Obstetrics, 2020, 301, 1299-1306.	1.7	6
56	Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study. Breast Care, 2019, 14, 41-47.	1.4	5
57	RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women. Scientific Reports, 2020, 10, 5171.	3.3	5
58	Should Breast Cancer Surgery Be Done in an Outpatient Setting?. Geburtshilfe Und Frauenheilkunde, 2017, 77, 879-886.	1.8	3
59	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians. Geburtshilfe Und Frauenheilkunde, 2018, 78, 707-714.	1.8	3
60	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center in Relation to Complementary and Alternative Medicine. Complementary Medicine Research, 2020, 27, 431-439.	1.2	3
61	Clinical and Preclinical Experience with Gefitinib and Sunitinib. Breast Care, 2007, 2, 68-73.	1.4	2
62	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the Guidelines. Breast Care, 2021, 16, 291-298.	1.4	2
63	Discordance between Primary Breast Cancer and Ipsilateral Breast Cancer Tumor Recurrence as a Function of Distance. Journal of Clinical Medicine, 2020, 9, 4033.	2.4	1
64	Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Breast Care, 2021, 16, 254-262.	1.4	0
65	Is Reduction Mammoplasty Cost-Effective? A Cost-Utility Analysis of Surgical Treatment for Macromastia in Germany. Breast Care, 2021, 16, 1-9.	1.4	0
66	Abstract 940: The contribution of common breast cancer susceptibility loci to the breast density and breast cancer association and the Breast Cancer Surveillance Consortium (BCSC) risk model. , 2014, , .		0